Background: The rise within the variety of most cancers circumstances and the evolution of most cancers care administration have turn out to be a big downside for the French well being care system, thereby making affected person empowerment as a protracted sought-after purpose in continual pathologies. The implementation of an activation measure through the Affected person Activation Measure-13 merchandise (PAM-13) in the midst of most cancers care can probably spotlight the affected person’s wants, with nursing care adapting accordingly.
Goal: The goals of this PARACT (PARAmedical Interventions on Affected person ACTivation) multicentric research have been as follows: (1) consider the implementation of PAM-13 in oncology nursing practices in 5 complete most cancers facilities, (2) determine the obstacles and facilitators to the implementation of PAM-13, and (3) produce suggestions for the dissemination of such interventions in different complete most cancers facilities.
Strategies: This research will comply with the “Attain, Effectiveness, Adoption, Implementation, and Upkeep” framework and can consist of three phases. First, a strong preimplementation evaluation will probably be performed utilizing the Theoretical Domains Framework (TDF) linked to the “Functionality, Alternative, Motivation, and Conduct” mannequin to determine the obstacles and facilitators to implementing new nursing practices in every context. Then, utilizing the Conduct Change Wheel, we are going to personalize a technique for implementing the PAM-13, relying on the specificities of every context, to encourage acceptability by the nursing employees concerned within the mission. This evaluation will probably be carried out through a qualitative research by way of semistructured interviews.
Second, the affected person will probably be included within the research for 12 months, throughout which the affected person care pathway will probably be studied, significantly to gather all related contacts of oncology nurses and different well being professionals concerned within the pathway. The axes of nursing care may even be collected. The first purpose is to implement PAM-13. Secondary elements to be measured are the affected person’s nervousness stage, high quality of life, and well being literacy stage. The oncology nurses will probably be liable for finishing the questionnaires when the affected person is on the hospital for his/her intravenous chemotherapy/immunotherapy remedy. The questionnaires will probably be accomplished thrice in a 12 months: (1) on the time of the affected person’s enrollment, (2) at 6 months, and (3) at 12 months. Third, a postimplementation evaluation will probably be carried out by way of semistructured interviews utilizing the TDF to research the implementation issues at every website.
Outcomes: This research was supported by a grant from the French Ministry of Well being (PHRIP PARACT 2016-0405) and the Lucien Neuwirth Institute of Cancerology of Saint-Etienne, France. Knowledge assortment for this research is ongoing.
Conclusions: This research would enhance the carried out focused nursing interventions in most cancers facilities so {that a} affected person is obtainable a customized most cancers care pathway. Moreover, measuring the extent of activation and the implementation of measures meant to extend such activation may represent a big benefit in decreasing social well being inequalities.
Navigating uncharted waters: Creating a standardized method for evaluating and implementing biosimilar merchandise at a complete most cancers middle
Goal: The processes for formulary implementation and digital well being file (EHR) integration of biosimilar merchandise at a complete most cancers middle are described. Implications for analysis protocols are additionally mentioned.
Abstract: The present literature focuses on sensible concerns for formulary addition of biosimilar merchandise, however there’s a lack of steering on how you can implement the change, significantly throughout the EHR. Earlier than constructing the ordering instruments for biosimilars, the scientific and informatics groups ought to decide the function of biosimilars on the establishment, determine drug-specific product traits that have an effect on treatment construct, and characterize implications of future formulary adjustments or drug shortages. Leveraging an orderable file supplies the power to incorporate logic that maps to a number of merchandise and in addition permits for future implementation of adjustments throughout the treatment file fairly than requiring “swaps” on the remedy protocol stage. The institutional overview board ought to coordinate adjustments in affected analysis protocols and consent kinds and work with principal investigators to amend protocols when obligatory. Pharmacy leaders ought to develop processes to supervise stock in the course of the transition interval and decrease the chance of errors.
Conclusion: The event of a standardized method for evaluating and implementing biosimilar merchandise improves effectivity and collaboration among the many numerous group members liable for the merchandise’ integration into present workflows, together with implications for scientific analysis. Implementing biosimilars for brokers used to deal with most cancers will pose new challenges and require extra concerns. Partial implementation of biosimilars continues to pose a number of challenges within the provision of affected person care.

Effect of PARACT (PARAmedical Interventions on Patient ACTivation) on the Cancer Care Pathway: Protocol for Implementation of the Patient Activation Measure-13 Item (PAM-13) Version
Matrix stiffness epigenetically regulates the oncogenic activation of the Sure-associated protein in gastric most cancers
In lots of cancers, tumour development is related to elevated tissue stiffness. But, the mechanisms associating tissue stiffness with tumorigenesis and malignant transformation are unclear. Right here we present that in gastric most cancers cells, the stiffness of the extracellular matrix reversibly regulates the DNA methylation of the promoter area of the mechanosensitive Sure-associated protein (YAP). Reciprocal interactions between YAP and the DNA methylation inhibitors GRHL2, TET2 and KMT2A may cause hypomethylation of the YAP promoter and stiffness-induced oncogenic activation of YAP.
BSA (Standard Grade) |
30-AB70 |
Fitzgerald |
1 kg |
EUR 899 |
Description: Standard Grade Bovine Serum Albumin (99% pure) |
Gastrointestinal Cancer Antigen (CA 19-9), antigen grade |
CA1991-N-10 |
Alpha Diagnostics |
10 KU |
EUR 529 |
Human Cancer Antigen 15-3 (CA 15-3) ELISA Kit |
PRB-5069 |
Cell Biolabs |
96 assays |
EUR 572 |
Human Cancer Antigen 15-3 (CA 15-3) ELISA Kit |
PRB-5069-5 |
Cell Biolabs |
5 x 96 assays |
EUR 2283 |
Cancer Antigen 15-3 MUC 1 Antigen (Human Milk) |
VAng-Cr3871-10kU |
Creative Biolabs |
10 kU |
EUR 421 |
Description: Cancer Antigen 15-3 MUC 1 Antigen, Host/Source: Human Milk. The purity is detected by salt extraction and delipidization following high speed centrifugation. It is tested negative for HBsAg, antibodies to HCV and HIV 1/2. |
Paraffin Tissue Section - Human Breast Tumor: Lobular carcinoma |
T2235086-3 |
Biochain |
5 slides |
EUR 257 |
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool. |
Breast Cancer-Associated Antigen BRCAA1 (BRCAA1) Antibody |
20-abx148333 |
Abbexa |
|
|
- Shipped within 5-10 working days.
|
Cancer Antigen 15-3 MUC 1 Antigen (Human Ascites Fluid) |
VAng-Cr3872-10kU |
Creative Biolabs |
10 kU |
EUR 1136 |
Description: Cancer Antigen 15-3 MUC 1 Antigen, Host/Source: Human Ascites Fluid. |
Cancer Antigen CA 15-3 Protein (Human Fluids) |
VAng-Wyb8628-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: CA 15-3 (Breast Cancer Antigen), Cancer antigen from Human Fluids, 12.240 kU/mL. |
Cancer Antigen CA 15-3 Protein (Human Milk) |
VAng-Wyb8631-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: CA 15-3 (Breast Cancer Antigen), Antigen Grade, Cancer antigen from Human Milk, 33.0 kIU/mL. |
Paraffin Tissue Section - Human Brain Tumor: Astrocytoma Grade III |
T2235035-3 |
Biochain |
5 slides |
EUR 257 |
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool. |
Cancer Antigen 15-3 (CA15-3) (human) ELISA Kit |
K4804-100 |
Biovision |
100 assays |
EUR 834 |
- Kit components:
- CA15-3 Ab-coated Microplate (Item A), 96 wells
- Wash Buffer (20x) (Item B)
- Human CA15-3 Standard (Item C)
- Assay Diluent A (Item D)
- Assay Diluent B (5x) (Item E)
- Detection Antibody (Item F)
- HRP-Streptavidin (200x) (Item
- Show more
|
Description: Sensitive, Colorimetric Assay |
Breast Cancer Exosome |
P141-BR |
101Bio |
NULL |
EUR 0 |
Human Cancer PrimaCell4: Breast Tumor Cells Growth Medium |
9-46027 |
CHI Scientific |
5 x 100 ml |
Ask for price |
Proteinase K, Recombinant, Standard Grade |
9250-100 |
Biovision |
|
EUR 104 |
Proteinase K, Recombinant, Standard Grade |
9250-10G |
Biovision |
|
EUR 3856 |
Proteinase K, Recombinant, Standard Grade |
9250-1G |
Biovision |
|
EUR 457 |
Proteinase K, Recombinant, Standard Grade |
9250-500 |
Biovision |
|
EUR 262 |
Proteinase K, Recombinant, Standard Grade |
9251-100 |
Biovision |
|
EUR 1055 |
Proteinase K, Recombinant, Standard Grade |
9251-25 |
Biovision |
|
EUR 294 |
Proteinase K, Recombinant, Standard Grade |
9251-5 |
Biovision |
|
EUR 120 |
Fluorescent Exosome Standard (Urine ) |
ESF-15 |
Creative Biolabs |
100 µg |
EUR 1723 |
Description: Fluorescent exosomes are labeled with green dye, which offer a stable fluorescent labeling. |
Human Cancer Tissue Preparation Buffer 4: Breast Tumor Cells |
9-80027 |
CHI Scientific |
1 x 100 ml |
Ask for price |
Breast Cancer Exosome RNA |
P241-BR |
101Bio |
NULL |
EUR 0 |
Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit |
DLR-CA15-3-Hu-48T |
DL Develop |
48T |
EUR 479 |
- Should the Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
|
Description: A sandwich quantitative ELISA assay kit for detection of Human Carbohydrate Antigen 15-3 (CA15-3) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit |
DLR-CA15-3-Hu-96T |
DL Develop |
96T |
EUR 621 |
- Should the Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
|
Description: A sandwich quantitative ELISA assay kit for detection of Human Carbohydrate Antigen 15-3 (CA15-3) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit |
RDR-CA15-3-Hu-48Tests |
Reddot Biotech |
48 Tests |
EUR 500 |
Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit |
RDR-CA15-3-Hu-96Tests |
Reddot Biotech |
96 Tests |
EUR 692 |
Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit |
RD-CA15-3-Hu-48Tests |
Reddot Biotech |
48 Tests |
EUR 478 |
Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit |
RD-CA15-3-Hu-96Tests |
Reddot Biotech |
96 Tests |
EUR 662 |
Polystyrene Particle Size Standard |
PPS-3 |
Spherotech |
mL |
EUR 127 |
Description: Please reffer to the technical data sheet for more detail information for this item. Our dedicated team would be happy to assist you via live chat, email or phone. |
Inactivated MuV Grade 3 Antigen |
VAng-Lsx0411-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: MuV grade 3, native protein. |
Inactivated Rotavirus Grade 3 Antigen |
VAng-Lsx0469-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: Rotavirus Grade 3, native virus. |
Inactivated RuV Grade 3 Antigen |
VAng-Lsx0476-1mL |
Creative Biolabs |
1 mL |
EUR 395 |
Description: RuV Grade 3, natural protein. |
Inactivated CMV Grade 3 Antigen |
VAng-Lsx0038-1mg |
Creative Biolabs |
1 mg |
EUR 2086 |
Description: CMV Grade 3, natural protein. |
99445-15 DCT 15 X 85MM |
99445-15 |
CORNING |
250/pk |
EUR 97 |
Description: Disposable Culture Tubes; DCT's, CGW |
CA 15-3, Human Breast Adenocarcinoma |
P1435-1 |
Biovision |
|
EUR 109 |
CA 15-3, Human Breast Adenocarcinoma |
P1435-5 |
Biovision |
|
EUR 240 |
Cancer Antigen 242 Antigen |
VAng-Cr3876-10kU |
Creative Biolabs |
10 kU |
EUR 421 |
Description: Cancer Antigen 242 Antigen, Host/Source: Metastatic Liver. The purity is detected by gel filtration. |
Cancer Antigen 50 Antigen |
VAng-Cr3877-50kU |
Creative Biolabs |
50 kU |
EUR 5535 |
Description: Cancer Antigen 50 Antigen, Host/Source: Human Cell Culture. It is tested negative for HBsAg, antibodies to HCV and HIV 1/2. |
Breast Cancer Metastasis Suppressor 1 |
PR27265 |
Neuromics |
2 ug |
EUR 191 |
Human CA15-3 Antigen Grade Protein |
abx060972-250kU |
Abbexa |
250 kU |
EUR 1984 |
- Shipped within 5-10 working days.
|
Inactivated PIV-3 Grade 2 Antigen |
VAng-Wyb3637-1mL |
Creative Biolabs |
1 mL |
EUR 1136 |
Description: Parainfluenza virus type 3 (strain C243) Grade 2, natural antigen |
Inactivated HSV-1 Grade 3 Antigen |
VAng-Lsx0293-1mg |
Creative Biolabs |
1 mg |
EUR 1489 |
Description: HSV Type 1 Grade III, native antigen. |
Inactivated HSV-2 Grade 3 Antigen |
VAng-Lsx0302-1mg |
Creative Biolabs |
1 mg |
EUR 1489 |
Description: HSV Type 2 Grade III, native antigen. |
Breast Tumor Kinase antibody |
70R-31875 |
Fitzgerald |
100 ug |
EUR 327 |
Description: Rabbit polyclonal Breast Tumor Kinase antibody |
Breast Tumor Kinase antibody |
70R-33385 |
Fitzgerald |
100 ug |
EUR 327 |
Description: Rabbit polyclonal Breast Tumor Kinase antibody |
Breast Tumor Kinase Antibody |
AF4768 |
Affbiotech |
200ul |
EUR 376 |
Description: Breast Tumor Kinase Antibody detects endogenous levels of Breast Tumor Kinase. |
Vitamin A Reference Standard (USP grade powder) |
51R-U716002 |
Fitzgerald |
10 pack |
EUR 516 |
Description: Vitamin A Reference Standard (USP grade powder) chemical reference substance |
CEA Antigen Grade Protein |
abx060976-05mg |
Abbexa |
0.5 mg |
EUR 968 |
- Shipped within 5-10 working days.
|
CEA Antigen Grade Protein |
abx060977-1mg |
Abbexa |
1 mg |
EUR 1692 |
- Shipped within 5-10 working days.
|
Prostate Specific Antigen Std Grade Antigen |
VAng-Cr3891-1mg |
Creative Biolabs |
1 mg |
EUR 504 |
Description: Prostate Specific Antigen Std Grade Antigen, Host/Source: Human Seminal Fluid. The purity is detected by salt precipitation. |
Breast Cancer-Associated Gene 3 Protein (BCA3) Antibody |
abx025588-400ul |
Abbexa |
400 ul |
EUR 523 |
- Shipped within 5-10 working days.
|
Breast Cancer-Associated Gene 3 Protein (BCA3) Antibody |
abx025588-80l |
Abbexa |
80 µl |
EUR 286 |
- Shipped within 5-10 working days.
|
Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Antibody |
20-abx129227 |
Abbexa |
-
EUR 425.00
-
EUR 133.00
-
EUR 1205.00
-
EUR 578.00
-
EUR 328.00
|
-
100 ug
-
10 ug
-
1 mg
-
200 ug
-
50 ug
|
- Shipped within 5-7 working days.
|
Breast Cancer-Associated Gene 3 Protein (BCA3) Antibody |
20-abx133658 |
Abbexa |
-
EUR 300.00
-
EUR 439.00
-
EUR 189.00
|
|
- Shipped within 5-10 working days.
|
Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Antibody |
20-abx171475 |
Abbexa |
|
|
|
Breast Cancer-Associated Gene 3 Protein (BCA3) Antibody |
20-abx013807 |
Abbexa |
-
EUR 314.00
-
EUR 98.00
-
EUR 398.00
-
EUR 495.00
|
-
100 ug
-
10 ug
-
200 ug
-
300 µg
|
- Shipped within 5-10 working days.
|
Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Antibody |
20-abx324781 |
Abbexa |
|
|
- Shipped within 5-10 working days.
|
Recombinant Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) |
4-RPG768Hu01 |
Cloud-Clone |
-
EUR 501.41
-
EUR 237.00
-
EUR 1605.28
-
EUR 601.76
-
EUR 1103.52
-
EUR 398.00
-
EUR 3863.20
|
-
100 ug
-
10ug
-
1 mg
-
200 ug
-
500 ug
-
50ug
-
5 mg
|
- Uniprot ID: O75815
- Buffer composition: PBS, pH 7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
- Form: Freeze-dried powder
- Predicted Molecular Mass (KD): 60.7kDa
- Isoelectric Point: Inquire
|
Description: Recombinant Human Breast Cancer Anti-Estrogen Resistance 3 expressed in: E.coli |
Cancer Antigen 72-4 Antigen |
VAng-Cr3878-10kU |
Creative Biolabs |
10 kU |
EUR 421 |
Description: Cancer Antigen 72-4 Antigen, Host/Source: Metastatic Liver. The purity is ~65% by SDS-PAGE. It is tested negative for HBsAg, antibodies to HCV and HIV 1/2. |
Autobioluminescent Human Breast Cancer Cells (MCF7) |
ASE-5903 |
Applied StemCell |
1 ml |
EUR 2075 |
Description: 6 month |
Autobioluminescent Human Breast Cancer Cells (T47D) |
ASE-5904 |
Applied StemCell |
1 ml |
EUR 2075 |
Description: 6 month |
Breast Cancer Metastasis Suppressor 1 Protein |
20-abx263402 |
Abbexa |
-
EUR 1609.00
-
EUR 328.00
-
EUR 230.00
|
|
- Shipped within 5-10 working days.
|
Breast Cancer Anti-Estrogen Resistance 1 |
PR27245 |
Neuromics |
2 ug |
EUR 191 |
anti-Breast cancer suppressor candidate 1 |
YF-PA12974 |
Abfrontier |
50 ul |
EUR 363 |
Description: Mouse polyclonal to Breast cancer suppressor candidate 1 |
anti-Breast cancer suppressor candidate 1 |
YF-PA12975 |
Abfrontier |
50 ug |
EUR 363 |
Description: Mouse polyclonal to Breast cancer suppressor candidate 1 |
anti-Breast cancer suppressor candidate 1 |
YF-PA24096 |
Abfrontier |
50 ul |
EUR 334 |
Description: Mouse polyclonal to Breast cancer suppressor candidate 1 |
Human Cancer Antigen CA15-3 Protein |
abx060965-50kU |
Abbexa |
50 kU |
EUR 2625 |
- Shipped within 5-10 working days.
|
9998 SCREW CAP 415/15 |
9998-15 |
CORNING |
288/pk |
EUR 198 |
Description: General Apparatus; Stoppers |
Breast Tumor Tissue Array - 16 cases of breast cancer, each in duplicates, paired with adjacent normal tissues |
Z7020007 |
Biochain |
5 slides |
EUR 1381 |
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool. |
Inactivated MuV Grade 3 Antigen (Strain Enders) |
VAng-0619Lsx-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: MuV (Strain Enders) grade 3, native protein. 0.45 mg/mL. |
Standard grade heat shock BSA powder, pH 7 |
BAH62-0050 |
Equitech |
50gm |
EUR 257.4 |
- Standard grade heat shock BSA powder, pH 7 is indicated as RUO. Do not use on humans.
|
Standard grade heat shock BSA powder, pH 7 |
BAH62-0100 |
Equitech |
100gm |
EUR 323.7 |
- Standard grade heat shock BSA powder, pH 7 is indicated as RUO. Do not use on humans.
|
Standard grade heat shock BSA powder, pH 7 |
BAH62-0500 |
Equitech |
500gm |
EUR 426.4 |
- Standard grade heat shock BSA powder, pH 7 is indicated as RUO. Do not use on humans.
|
Standard grade heat shock BSA powder, pH 7 |
BAH62-1000 |
Equitech |
1KG |
Ask for price |
- Standard grade heat shock BSA powder, pH 7 is indicated as RUO. Do not use on humans.
|
Standard grade heat shock BSA powder, pH 7 |
BAH62-10000 |
Equitech |
10KG |
Ask for price |
- Standard grade heat shock BSA powder, pH 7 is indicated as RUO. Do not use on humans.
|
Standard grade heat shock BSA powder, pH 5.2 |
BAH63-0050 |
Equitech |
50gm |
EUR 257.4 |
- Standard grade heat shock BSA powder, pH 5.2 is indicated as RUO. Do not use on humans.
|
Standard grade heat shock BSA powder, pH 5.2 |
BAH63-0100 |
Equitech |
100gm |
EUR 323.7 |
- Standard grade heat shock BSA powder, pH 5.2 is indicated as RUO. Do not use on humans.
|
Standard grade heat shock BSA powder, pH 5.2 |
BAH63-0500 |
Equitech |
500gm |
EUR 426.4 |
- Standard grade heat shock BSA powder, pH 5.2 is indicated as RUO. Do not use on humans.
|
Standard grade heat shock BSA powder, pH 5.2 |
BAH63-1000 |
Equitech |
1KG |
Ask for price |
- Standard grade heat shock BSA powder, pH 5.2 is indicated as RUO. Do not use on humans.
|
Standard grade heat shock BSA powder, pH 5.2 |
BAH63-10000 |
Equitech |
10KG |
Ask for price |
- Standard grade heat shock BSA powder, pH 5.2 is indicated as RUO. Do not use on humans.
|
Breast Tumor Kinase antibody (Tyr447) |
70R-33384 |
Fitzgerald |
100 ug |
EUR 327 |
Description: Rabbit polyclonal Breast Tumor Kinase antibody (Tyr447) |
Breast Tumor Kinase Blocking Peptide |
AF4768-BP |
Affbiotech |
1mg |
EUR 195 |
Breast Cancer Anti-Estrogen Resistance Protein 3 (BCAR3) Antibody |
abx010337-100ug |
Abbexa |
100 ug |
EUR 439 |
- Shipped within 5-10 working days.
|
Breast Cancer Anti-Estrogen Resistance Protein 3 (BCAR3) Antibody |
abx218562-100ug |
Abbexa |
100 ug |
EUR 439 |
- Shipped within 5-10 working days.
|
Breast Cancer Anti-Estrogen Resistance Protein 3 (BCAR3) Antibody |
20-abx134976 |
Abbexa |
-
EUR 356.00
-
EUR 537.00
-
EUR 217.00
|
|
- Shipped within 5-10 working days.
|
Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Protein |
20-abx168253 |
Abbexa |
-
EUR 704.00
-
EUR 286.00
-
EUR 2165.00
-
EUR 829.00
-
EUR 495.00
|
-
100 ug
-
10 ug
-
1 mg
-
200 ug
-
50 ug
|
- Shipped within 5-7 working days.
|
Cancer of the breast, 75 cases (1.1mm), set 3 |
BRC1503 |
Pantomics |
1 |
EUR 250 |
Description: Breast cancer tissue array, set 3, non-overlapping with BRC1501, BRC1502, BRC1504 to BRC15011,150 cores from normal/benign (5 cases) and cancer (70 cases) tissues in duplicates with grading, TNM staging data, AR, ER, PR, HER2, P53, EGFR, Ki67 IHC data. |
Breast Cancer Anti-Estrogen Resistance Protein 3 (BCAR3) Antibody |
abx432398-200ul |
Abbexa |
200 ul |
EUR 384 |
- Shipped within 1-3 working days.
|
Breast Cancer Estrogen Resistance 3 (BCAR3) Polyclonal Antibody (Human) |
4-PAG768Hu01 |
Cloud-Clone |
-
EUR 247.00
-
EUR 2510.00
-
EUR 625.00
-
EUR 310.00
-
EUR 214.00
|
-
100ul
-
10ml
-
1ml
-
200ul
-
20ul
|
- Sequence of the immunogen: BCAR3 (Asp548~Pro818)
- Buffer composition: PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
|
Description: A Rabbit polyclonal antibody against Human Breast Cancer Estrogen Resistance 3 (BCAR3) |
Cancer Antigen CEA Antigen (Human Fluids) |
VAng-Wyb8644-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: Carcinoembryonic Antigen, Calibrator Grade, Cancer antigen from Human Fluids, 1.13 mg/mL. |
Cancer Antigen 125 Antigen (Human Adenocarcinoma) |
VAng-Cr3868-10kU |
Creative Biolabs |
10 kU |
EUR 421 |
Description: Cancer Antigen 125 Antigen, Host/Source: Human Adenocarcinoma. The purity is detected by salt extraction and chromatography. |
Cancer Antigen 125 Antigen (Ascites Fluid) |
VAng-Cr3870-10kU |
Creative Biolabs |
10 kU |
EUR 944 |
Description: Cancer Antigen 125 Antigen, Host/Source: Ascites Fluid. The purity is ≥ 95% by SDS-PAGE. |
ODN M362-Type C human/murine TLR9 agonist-antigen grade-antigen grade |
ODNM362-1 |
Alpha Diagnostics |
1 mg |
EUR 651 |
ODN M362-Type C human/murine TLR9 agonist-antigen grade-antigen grade |
ODNM362-5 |
Alpha Diagnostics |
5 mg |
EUR 1991 |
Human Cancer Antigen CA125 (Ovarian Cancer) Protein |
abx061590-100kU |
Abbexa |
100 kU |
EUR 1205 |
- Shipped within 5-10 working days.
|
Ck-Mm Antigen Grade Protein |
abx060710-1mg |
Abbexa |
1 mg |
EUR 648 |
- Shipped within 5-10 working days.
|
Human AFP Antigen Grade Protein |
abx060957-1mg |
Abbexa |
1 mg |
EUR 926 |
- Shipped within 5-10 working days.
|
Human AFP Antigen Grade Protein |
abx060958-1mg |
Abbexa |
1 mg |
EUR 1316 |
- Shipped within 5-10 working days.
|
Human AFP Antigen Grade Protein |
abx060959-1mg |
Abbexa |
1 mg |
EUR 996 |
- Shipped within 5-10 working days.
|
Human CA125 Antigen Grade Protein |
abx060960-50kU |
Abbexa |
50 kU |
EUR 801 |
- Shipped within 5-10 working days.
|
Imidazoquinoline (TLR7 Agonist) Antigen Grade |
VAdv-Ly0018-25mg |
Creative Biolabs |
25 mg |
EUR 3610 |
Description: Imidazoquinoline, a TLR7 agonist vaccine adjuvant. |
Imidazoquinoline (TLR7 Agonist) Antigen Grade |
VAdv-Ly0018-5mg |
Creative Biolabs |
5 mg |
EUR 861 |
Description: Imidazoquinoline, a TLR7 agonist vaccine adjuvant. |
Recombinant CEA Protein (Antigen Grade) |
VAng-Wyb8647-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: Carcinoembryonic Antigen, Antigen Grade, recombinant protein from Cell Culture, 3.71 mg/mL. |
Inactivated VZV Grade 2 Antigen |
VAng-Lsx0555-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: VZV Grade 2, native virus. |
Inactivated MeV Grade 2 Antigen |
VAng-Lsx0384-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: Measles Grade 2, native virus. |
Inactivated MuV Grade 2 Antigen |
VAng-Lsx0409-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: MuV Grade 2, native virus. |
Inactivated RuV Grade 2 Antigen |
VAng-Lsx0475-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: RuV Grade 2, natural protein. |
Inactivated RuV Grade 4 Antigen |
VAng-Lsx0477-1mg |
Creative Biolabs |
1 mg |
EUR 3080 |
Description: RuV Grade 4, natural antigen. |
Inactivated CMV Grade 2 Antigen |
VAng-Lsx0037-1mg |
Creative Biolabs |
1 mg |
EUR 2027 |
Description: CMV Grade 2, natural protein. |
Inactivated ADV Grade 2 Antigen |
VAng-Lsx0003-1mL |
Creative Biolabs |
1 mL |
EUR 998 |
Description: ADV Grade 2, natural antigen. |
Recombinant (E. coli) Dengue Virus Type 3 E Antigen (DENV-E), antigen grade (>95%, 15 kda, no tag) |
RP-1596 |
Alpha Diagnostics |
50 ug |
EUR 408 |
Paraffin Tissue Section - Human Breast Tumor: Male Breast Hyperplasia |
T2235086-4 |
Biochain |
5 slides |
EUR 257 |
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool. |
Paraffin Tissue Section - Human Breast Tumor: Medullarycarcinoma of Breast |
T2235086-5 |
Biochain |
5 slides |
EUR 257 |
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool. |
Recombinant Human IL-15 Protein |
PROTP40933-3 |
BosterBio |
10ug |
EUR 317 |
Description: IL-15 is an immunomodulating cytokine that stimulates the proliferation of T lymphocytes and shares many biological properties with IL-2. IL-15 exerts its biological activites primarily on T cells. It is also essential in the development, survival and activation of NK cells. Increased expression of IL-15 has been implicated with rheumatoid arthritis, inflammatory bowel disease and diseases affiliated with retroviruses HIV and HTLV-I. Human IL-15 is biologically active on mouse cells as measured by the dose-dependent stimulation of the proliferation of mouse CTLL cells. Recombinant human IL-15 is a 12.9 kDa protein consisting of 114 amino acid residues. |
Swine IL-15 Recombinant Protein |
R00212-3 |
BosterBio |
5ug/vial |
EUR 259 |
Description: Interleukin-15 (IL-15) is a cytokine with structural similarity to IL-2 that is secreted by mononuclear phagocytes following infection by virus(es). This cytokine induces cell proliferation of natural killer cells. Swine IL-15 Recombinant Protein is purified interleukin-15 produced in yeast. |
Paraffin Tissue Section - Human Pancreas Tumor: Islet Cell Tumor |
T2235188-3 |
Biochain |
5 slides |
EUR 257 |
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool. |
Breast cancer-overexpressed gene 1 protein Antibody |
48092-100ul |
SAB |
100ul |
EUR 333 |
Breast cancer-overexpressed gene 1 protein Antibody |
48092-50ul |
SAB |
50ul |
EUR 239 |
Human Breast cancer metastasis-suppressor 1 (BRMS1) |
1-CSB-RP048144h |
Cusabio |
-
EUR 380.00
-
EUR 214.00
-
EUR 1309.00
-
EUR 560.00
-
EUR 873.00
-
EUR 262.00
|
-
100ug
-
10ug
-
1MG
-
200ug
-
500ug
-
50ug
|
- MW: 54.3 kDa
- Buffer composition: Tris-based buffer with 50% glycerol.
|
Description: Recombinant Human Breast cancer metastasis-suppressor 1(BRMS1),partial expressed in E.coli |
Breast Cancer Metastasis-Suppressor 1 (BRMS1) Antibody |
20-abx008216 |
Abbexa |
-
EUR 300.00
-
EUR 439.00
-
EUR 189.00
|
|
- Shipped within 5-10 working days.
|
Breast Cancer Metastasis-Suppressor 1 (BRMS1) Antibody |
20-abx008217 |
Abbexa |
-
EUR 300.00
-
EUR 439.00
-
EUR 189.00
|
|
- Shipped within 5-10 working days.
|
Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody |
20-abx175628 |
Abbexa |
|
|
|
Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody |
20-abx104049 |
Abbexa |
-
EUR 411.00
-
EUR 133.00
-
EUR 1149.00
-
EUR 565.00
-
EUR 314.00
|
-
100 ug
-
10 ug
-
1 mg
-
200 ug
-
50 ug
|
- Shipped within 5-7 working days.
|
Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody |
20-abx104050 |
Abbexa |
-
EUR 439.00
-
EUR 133.00
-
EUR 1247.00
-
EUR 592.00
-
EUR 328.00
|
-
100 ug
-
10 ug
-
1 mg
-
200 ug
-
50 ug
|
- Shipped within 5-7 working days.
|
Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody |
20-abx104051 |
Abbexa |
-
EUR 411.00
-
EUR 133.00
-
EUR 1149.00
-
EUR 565.00
-
EUR 314.00
|
-
100 ug
-
10 ug
-
1 mg
-
200 ug
-
50 ug
|
- Shipped within 5-7 working days.
|
Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody |
20-abx129675 |
Abbexa |
-
EUR 425.00
-
EUR 133.00
-
EUR 1177.00
-
EUR 578.00
-
EUR 328.00
|
-
100 ug
-
10 ug
-
1 mg
-
200 ug
-
50 ug
|
- Shipped within 5-7 working days.
|
Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody |
20-abx129746 |
Abbexa |
-
EUR 300.00
-
EUR 133.00
-
EUR 801.00
-
EUR 425.00
-
EUR 258.00
|
-
100 ug
-
10 ug
-
1 mg
-
200 ug
-
50 ug
|
- Shipped within 5-7 working days.
|
Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody |
20-abx130340 |
Abbexa |
-
EUR 439.00
-
EUR 133.00
-
EUR 1233.00
-
EUR 592.00
-
EUR 328.00
|
-
100 ug
-
10 ug
-
1 mg
-
200 ug
-
50 ug
|
- Shipped within 5-7 working days.
|
Breast Cancer Cell Protein 2 (BRCC2) Antibody |
20-abx141388 |
Abbexa |
-
EUR 370.00
-
EUR 606.00
-
EUR 300.00
|
|
- Shipped within 5-10 working days.
|
Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody |
20-abx171476 |
Abbexa |
|
|
|
Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody |
20-abx171477 |
Abbexa |
|
|
|
Breast Cancer Metastasis-Suppressor 1 (BRMS1) Antibody |
abx030985-400ul |
Abbexa |
400 ul |
EUR 523 |
- Shipped within 5-10 working days.
|
Breast Cancer Metastasis-Suppressor 1 (BRMS1) Antibody |
abx030985-80l |
Abbexa |
80 µl |
EUR 286 |
- Shipped within 5-10 working days.
|
Breast Cancer Metastasis-Suppressor 1 (BRMS1) Antibody |
20-abx241361 |
Abbexa |
|
|
- Shipped within 5-10 working days.
|
Breast Cancer Metastasis-Suppressor 1 (BRMS1) Antibody |
20-abx241362 |
Abbexa |
|
|
- Shipped within 5-10 working days.
|
Direct alteration of extracellular cues through in situ matrix softening reversed YAP exercise and the epigenetic program. Our findings recommend that epigenetic reprogramming of the mechanophysical properties of the extracellular microenvironment of stable tumours might symbolize a therapeutic technique for the inhibition of most cancers development.